<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483041</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP139</org_study_id>
    <nct_id>NCT00483041</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528</brief_title>
  <official_title>A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of MEDI-528 in adults with atopic asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of MEDI-528 on the change in biologically active IL-9 levels in BAL
      fluid following segmental allergen challenge in adults with atopic asthma.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study is replaced by MI-CP198 per CPM.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Listing of Total Interleukin-9 (IL-9) Counts by Enzyme-linked Immunosorbent Assay in Bronchoalveolar Lavage Fluid (BAL)</measure>
    <time_frame>Baseline (2 to 4 weeks prior to Day 0) and Day 15</time_frame>
    <description>The response of biologically active IL-9 in BAL fluid to the segmental allergen challenge, 1-2 days after the applying the allergen, prior to and 2 weeks after investigational product administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Days 0 - 126</time_frame>
    <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Days 0 - 126</time_frame>
    <description>Number of participants experiencing serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</measure>
    <time_frame>Days 0, 28, 56, 84, and 126</time_frame>
    <description>Number of participants with ADA to MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Concentration (Tmax)</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>Tmax of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Concentration (Cmax)</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>Cmax of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>AUC(0-t) of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>AUC(0-infinity) of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>AUC(ext) of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>CL of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (T1/2)</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>T1/2 of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume at Steady State (Vss)</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>Vss of MEDI-528</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume at Distribution (Vz)</measure>
    <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
    <description>Vz of MEDI-528</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MEDI528 9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Placebo administered as a single intravenous infusion</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI528 9 mg/kg</intervention_name>
    <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
    <arm_group_label>MEDI528 9 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults, age 18 through 50 years of age at time of screening;

          -  Written informed consent obtained from the patient prior to receipt of any study
             medication or beginning any study procedures;

          -  Previously documented diagnosis of asthma based on episodic symptoms of airflow
             obstruction such as wheezing or chest tightness, with alternative diagnoses (eg,
             chronic obstructive pulmonary disease) ruled out;

          -  Forced expiratory volume in one second (FEV1) ≥ 70% of predicted value;

          -  A positive skin prick or intradermal test to cat allergen extract, short ragweed
             allergen extract, or dust mite allergen extracts. A positive skin test is defined as
             the indurations of skin test wheal being at least 2 mm greater in diameter than that
             of the indurations of the control skin wheal;

          -  History of asthmatic symptoms upon exposure to at least one of the allergens (cat
             allergen extract, short ragweed allergen extract, or dust mite allergen extracts) that
             induces a positive skin prick test;

          -  AHR on methacholine inhalation challenge test, with PC20 ≤ 8 mg/mL (Crapo, 2000);

          -  No significant changes in regular asthma medications and no acute asthma exacerbations
             requiring oral corticosteroids or doubling of ICS dosage, hospitalization, emergency
             room visits, or unscheduled health care provider visits for asthma for at least 6
             weeks prior to screening and up through the time of study drug administration;

          -  No history of intubation or admission to an intensive care unit for asthma;

          -  Sexually active women, unless surgically sterile or at least 1 year post-menopausal,
             must have used an effective method of avoiding pregnancy (including oral or implanted
             contraceptives, intrauterine device, female condom, diaphragm with spermicide,
             cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual
             partner) for 21 days prior to the study drug administration on Study Day 0, and must
             agree to continue using such precautions through Study Day 126. Cessation of birth
             control after this point should be discussed with a responsible physician. Sexually
             active men, unless surgically sterile, must likewise use an effective method of birth
             control (condom) and must agree to continue using such precautions through Study Day
             126;

          -  Able to follow study procedures including the ability to provide spirometry readings
             that meet American Thoracic Society (ATS)/European Respiratory Society (ERS) standards
             (Miller, 2005);

          -  Ability to complete the study period, including follow-up period, of up to 126 days;
             and

          -  Willing to forego other forms of experimental treatment and study procedures during
             study.

        Exclusion Criteria:

          -  Receipt of MEDI-528 in any previous clinical study;

          -  History of allergy or reaction to any component of the study drug formulation or other
             medications, such as topical lidocaine, administered during bronchoscopy;

          -  Lung disease other than allergic asthma (eg, chronic bronchitis);

          -  FEV1 &lt; 70% of predicted values;

          -  Use of systemic immunosuppressive drugs including systemic corticosteroids (topical
             corticosteroids are permitted), ICS at doses &gt; 800 μg/day budesonide or equivalent,
             long-acting β2 agonists (eg, salmeterol), leukotriene antagonists, cromolyn sodium,
             nedocromil sodium, theophylline, omalizumab, or any other medication for asthma except
             short-acting β2 agonist (as needed) within the 4 weeks prior to screening up through
             administration of study drug;

          -  Current use of any β-adrenergic antagonist (eg, propranolol);

          -  Any disease or illness, other than asthma, that may require the use of systemic
             corticosteroids during the study period;

          -  Upper or lower respiratory tract infections within 8 weeks before screening;

          -  Acute illnesses or evidence of clinically significant active infection, such as fever
             ≥ 38.0°C (100.5°F) at screening and through the time of the study drug administration
             on Study Day 0;

          -  Current allergy vaccination therapy (desensitization immunotherapy) with less than 3
             months of stable maintenance doses prior to the baseline segmental allergen challenge.
             The allergy vaccination must not include desensitization to the allergen that will be
             used in the segmental allergen challenge;

          -  Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5
             half-lives of the agent prior to study drug administration through Study Day 126;

          -  Receipt of any therapy with a leukocyte-depleting agent (eg, rituximab, alemtuzumab)
             unless recovery in white cell count has been documented before screening;

          -  Pregnancy (sexually active females must have negative serum and urine pregnancy tests
             at screening and a negative urine pregnancy test prior to study drug administration on
             Study Day 0);

          -  Is a nursing mother at the time of screening;

          -  Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active
             infection with hepatitis A;

          -  History of significant systemic disease (eg, cancer, infection, hematological, renal,
             hepatic, coronary artery disease or other cardiovascular disease, endocrinologic,
             neurologic, rheumatologic, or gastrointestinal disease);

          -  History of cancer other than basal cell carcinoma or cervical carcinoma-in-situ
             treated with apparently successful curative therapy (remission for ≥ 1 year prior to
             screening);

          -  History of primary immunodeficiency;

          -  History of pancreatitis or currently active gastroduodenal ulcer;

          -  History of coagulation disorders or abnormal PT and PTT test results at screening;

          -  History of life-long urinary retention;

          -  History of use of tobacco products of more than one cigarette per month or equivalent
             within 1 year prior to screening or history of smoking of ≥ 10 pack-years;

          -  History of anaphylaxis;

          -  Elective surgery planned from the time of screening through Study Day 126;

          -  Clinically significant abnormalities (other than asthma) upon physical examination
             prior to study drug administration on Study Day 0;

          -  Clinically significant abnormality, as determined by the investigator, on 12-lead ECG
             or chest radiograph at the time of screening;

          -  At the time of screening, any of the following: hemoglobin, total white blood cell
             count (WBC), platelet count, sodium (Na), potassium (K), chloride (Cl), or carbon
             dioxide (CO2)out of the normal range; aspartate transaminase (AST), alanine
             transaminase (ALT), blood urea nitrogen (BUN), amylase, lipase, or serum creatinine
             above the upper limits of normal (ULN); or other abnormal laboratory values in the
             screening panel that are judged by the principal investigator to be clinically
             significant; or

          -  No detectable levels of IL-9 in the Baseline Visit 2' BAL sample, or any finding upon
             physical examination or history of any disease that, in the opinion of the principal
             investigator or medical monitor, may compromise the safety of the patient in the study
             or confound the analysis of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Parker, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital Asthma Research</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univeristy School of Medicine, Division of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University, Baptist Medicial Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin, Section of Allergy, Pulmonary &amp; Critical Care</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2007</study_first_posted>
  <results_first_submitted>October 22, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2014</results_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 11 adult participants participated in the study between 19Jul2007 and 15Oct2008 at 2 sites in the United States of America.</recruitment_details>
      <pre_assignment_details>Treatment assignments were determined using a block randomization procedure with a 1:1 ratio through an interactive voice response system. Only participants who had detectable levels of interleukin-9 in the Baseline Visit 2’ bronchioalveolar lavage sample will be randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PLACEBO</title>
          <description>Placebo administered as a single intravenous dose</description>
        </group>
        <group group_id="P2">
          <title>MEDI528 9 mg</title>
          <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ABNORMAL LAB DATA AT SCREENING</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PLACEBO</title>
          <description>Placebo administered as a single intravenous dose</description>
        </group>
        <group group_id="B2">
          <title>MEDI528 9 mg</title>
          <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="7.8"/>
                    <measurement group_id="B2" value="22.3" spread="2.7"/>
                    <measurement group_id="B3" value="25.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Listing of Total Interleukin-9 (IL-9) Counts by Enzyme-linked Immunosorbent Assay in Bronchoalveolar Lavage Fluid (BAL)</title>
        <description>The response of biologically active IL-9 in BAL fluid to the segmental allergen challenge, 1-2 days after the applying the allergen, prior to and 2 weeks after investigational product administration.</description>
        <time_frame>Baseline (2 to 4 weeks prior to Day 0) and Day 15</time_frame>
        <population>All subjects who were randomized (n=11), received at least one dose of investigational product (MEDI-528 or placebo; n=10), and completed the 2-day BAL and segmental allergen challenge procedures at baseline (2-4 weeks prior to Day 0) and on Days 14 and 15 (n=2; 1 subject in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Listing of Total Interleukin-9 (IL-9) Counts by Enzyme-linked Immunosorbent Assay in Bronchoalveolar Lavage Fluid (BAL)</title>
          <description>The response of biologically active IL-9 in BAL fluid to the segmental allergen challenge, 1-2 days after the applying the allergen, prior to and 2 weeks after investigational product administration.</description>
          <population>All subjects who were randomized (n=11), received at least one dose of investigational product (MEDI-528 or placebo; n=10), and completed the 2-day BAL and segmental allergen challenge procedures at baseline (2-4 weeks prior to Day 0) and on Days 14 and 15 (n=2; 1 subject in each treatment group).</population>
          <units>Picograms per milliliter</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" spread="0"/>
                    <measurement group_id="O2" value="4.04" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.05"/>
                    <measurement group_id="O2" value="43.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
        <time_frame>Days 0 - 126</time_frame>
        <population>All participants who were randomized (n=11) and received at least one dose of investigational product (MEDI-528 or placebo; n=10).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of participants experiencing adverse events (includes both adverse events and serious adverse events)</description>
          <population>All participants who were randomized (n=11) and received at least one dose of investigational product (MEDI-528 or placebo; n=10).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of participants experiencing serious adverse events</description>
        <time_frame>Days 0 - 126</time_frame>
        <population>All participants who were randomized (n=11) and received at least one dose of investigational product (MEDI-528 or placebo; n=10).</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of participants experiencing serious adverse events</description>
          <population>All participants who were randomized (n=11) and received at least one dose of investigational product (MEDI-528 or placebo; n=10).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
        <description>Number of participants with ADA to MEDI-528</description>
        <time_frame>Days 0, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11) and received at least one dose of investigational product (MEDI-528 or placebo; n=10). One subject in the 9 mg/kg group had no sample collected on Day 126.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Anti-drug Antibodies (ADA) to MEDI-528</title>
          <description>Number of participants with ADA to MEDI-528</description>
          <population>All participants who were randomized (n=11) and received at least one dose of investigational product (MEDI-528 or placebo; n=10). One subject in the 9 mg/kg group had no sample collected on Day 126.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Concentration (Tmax)</title>
        <description>Tmax of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Concentration (Tmax)</title>
          <description>Tmax of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.040" spread="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Concentration (Cmax)</title>
        <description>Cmax of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Concentration (Cmax)</title>
          <description>Cmax of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="210.634" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
        <description>AUC(0-t) of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]</title>
          <description>AUC(0-t) of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Microgram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4347.489" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
        <description>AUC(0-infinity) of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]</title>
          <description>AUC(0-infinity) of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Microgram times day per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4845.344" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
        <description>AUC(ext) of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]</title>
          <description>AUC(ext) of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Percentage of Total Area</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.283" spread="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL)</title>
        <description>CL of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>CL of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Milliliters per day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="167.702" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (T1/2)</title>
        <description>T1/2 of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T1/2)</title>
          <description>T1/2 of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="32.134" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume at Steady State (Vss)</title>
        <description>Vss of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume at Steady State (Vss)</title>
          <description>Vss of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7354.025" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume at Distribution (Vz)</title>
        <description>Vz of MEDI-528</description>
        <time_frame>Days 0, 1, 7, 14, 15, 28, 56, 84, and 126</time_frame>
        <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo administered as a single intravenous dose</description>
          </group>
          <group group_id="O2">
            <title>MEDI528 9 mg/kg</title>
            <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume at Distribution (Vz)</title>
          <description>Vz of MEDI-528</description>
          <population>All participants who were randomized (n=11), received MEDI-528 (n=5), and had pharmacokinetic samples for analysis (n=4)</population>
          <units>Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7772.894" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
          <description>Placebo administered as a single intravenous dose</description>
        </group>
        <group group_id="E2">
          <title>MEDI528 9 mg</title>
          <description>MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="15" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Parker, MD</name_or_title>
      <organization>MedImmune</organization>
      <phone>301-398-0000</phone>
      <email>parkerj@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

